New combo therapy aims to delay ovarian cancer return
NCT ID NCT04742075
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of three drugs—olaparib, durvalumab, and a cancer vaccine called UV1—can help keep ovarian cancer from coming back after chemotherapy. The study includes 188 patients with recurrent ovarian cancer who do not have BRCA mutations. Participants are randomly assigned to receive either the triple combination or standard treatment to see which works better at delaying cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olaparib, durvalumab, and UV1 vaccine
What this could lead to
If successful, this could offer a new maintenance treatment option to delay cancer progression in patients with recurrent ovarian cancer who do not have BRCA mutations.
What could go wrong
This is an early phase 2 trial with a small number of participants, so results may not confirm benefit. The combination therapy may cause significant side effects and may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rigshospitalet
København Ø, Region Sjælland, 2100, Denmark